Selective glucocorticoid receptor agonists
US7763596B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 19, 2007 |
| Grant date | Jul 27, 2010 |
| Priority date | — |
| Expiry date | Jun 12, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J41/0038
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which comprises administering to a patient a compound that has the structure of Formula (I) or Formula (II) as defined below, or a pharmaceutically acceptable derivative thereof or pro-drug therefor, wherein R═NH2, NHR1, NHOR2, NHNHR2, NHCOR2, and R1═C(1-4)alkyl, C(3-6)cycloalkyl, Cn, where n=1-3, R2=methyl, ethyl, R3=alkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, aryl, heteroaryl, substituted aryl, or substituted hetrecoaryl; wherein R4, R5═C(1-4)alkyl. Novel compounds according to Formula (III), wherein R6 and R7 are any of H, CH3CO, CH3CH2CO, CH3CH2CH2CO provided that R6 and R7 are not both H, or Formula (IV), wherein R8 and R9 are any of H, CH3CO, CH3CH2CO or CH3CH2CH2CO, having use in such methods, are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.